To include your compound in the COVID-19 Resource Center, submit it here.

Imprimis, Buderer Drug deal

Imprimis acquired rights to undisclosed IP from compounding pharmacy Buderer and received a right of first refusal for

Read the full 185 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE